Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Accounts Payables (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Accounts Payables for 2 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 48.49% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 48.49% year-over-year, with the annual reading at $4.0 million for FY2025, 48.49% down from the prior year.
  • Accounts Payables hit $4.0 million in Q4 2025 for Prelude Therapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $7.7 million in Q4 2024 to a low of $2.5 million in Q3 2025.